Clinical Trials
7 trialsNCT03784014 2026-04-29
MULTISARC
Institut National de la Santé Et de la Recherche Médicale, France
Phase 3 Completed
NCT02000622 2026-02-13
OlympiAD
AstraZeneca
Phase 3 Completed
NCT02898207 2023-04-26
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00707707 2018-03-06
Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer
AstraZeneca
Phase 1 Completed
NCT01583543 2017-05-19
Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
Massachusetts General Hospital
Phase 2 Completed
NCT00710268 2015-01-14
Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT00633269 2009-01-14
Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours
AstraZeneca
Phase 1 Completed